1
Orphan Designations
1 approved
1
FDA Approvals
Latest: DAXXIFY (2022)
0
Active Trials
4
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Revance Therapeutics, Inc. is a company with 1 orphan drug designation across 4 rare diseases, including 1 FDA-approved therapy.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| benign essential blepharospasm | DAXXIFY | Des.TrialAppr. |
| cervical dystonia | DAXXIFYDaxxify | Des.TrialAppr. |
| clonic hemifacial spasm | DAXXIFY | Des.TrialAppr. |
| combined cervical dystonia | DAXXIFY | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
4
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
4
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio